Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesEffects of Transdermal Buprenorphine on Patients-reported Outcomes in Cancer Patients: Results From the Cancer Pain Outcome Research (CPOR) Study Group
The Clinical Journal of Pain, 09/25/09
Apolone G et al. – Despite the limitations owing to the observational design, these findings may be useful to clinicians to judge the value of the drug under evaluation better and to help researchers design further comparative studies.
Methods- A multicenter, open–label, prospective, nonrandomized study.
- Data were collected using a web–based standardized system, with a follow–up up of to 3 months.
- Pain intensity, the primary outcomes of the study, was measured using 11–point numerical rating scales from the Brief Pain Inventory.
- 110 centers recruited 1801 cases, most of which (60%) were receiving a strong opioid at the time of inclusion. Of these, 257 had TDS buprenorphine as first choice.
- Of the remaining 709 patients who at the time of inclusion were not on a strong opioid, 325 changed to a strong opioid and in 43% it was TDS buprenorphine.
- During the follow–up, physicians had to increase the dosage to control pain (average increase between 16% and 17%).
- About 34% of patients had an improvement of at least 2 points in worst pain, 15% had a 20% improvement in pain relief, and 40% in satisfaction.
Related Articles
The Use of Transdermal Fentanyl in Cancer Pain: A Compliance Study of Outpatients in Taiwan
American Journal of Hospice and Palliative Medicine, 10/05/09
Relevance Score: 87%
Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational study
Clinical Therapeutics, 11/19/09
Relevance Score: 81%
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain
Current Medical Research and Opinion, 10/13/09
Relevance Score: 80%
Transdermal Fentanyl: Pharmacology and Toxicology
Journal of Medical Toxicology, 11/02/09
Relevance Score: 78%
Paraneoplastic dermatological manifestation of gastrointestinal malignancies
World Journal of Gastroenterology, 10/01/09
Relevance Score: 77%
Today in Pain Management/Palliative Care...keeping you current
Receive free subspecialty "5-minute updates" via email
Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: A randomized, double-blind, placebo-controlled study
Annals of Oncology, 11/30/09
The Role of Interventional Therapies in Cancer Pain Management
Annals, Academy of Medicine, Singapore, 11/30/09
Paracentesis in Ovarian Cancer: A Study of the Physiology during Free Drainage of Ascites
Journal of Palliative Medicine, 11/30/09
Sponsor
Article Search
Sponsor
Sponsor